bupropion has been researched along with Stroke in 6 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation." | 7.85 | Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. ( Ascher, J; Hasselblad, V; Huang, M; Kittle, J; Kolls, BJ; Krishen, A; Lopes, RD; Mahaffey, KW; Marquess, ML; McGuire, DK; Roe, MT; Russell, SD; Wilson, MD, 2017) |
| "To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion." | 7.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "To calculate incremental cost-utility ratios (cost per quality-adjusted life-year [QALY] gained) for bupropion (Zyban; GlaxoSmithKline; Gothenburg, Sweden), as compared to nicotine replacement therapy (NRT) in smoking cessation programs for a follow-up period of 20 years." | 7.73 | The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. ( Bolin, K; Lindgren, B; Willers, S, 2006) |
| "In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation." | 3.85 | Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. ( Ascher, J; Hasselblad, V; Huang, M; Kittle, J; Kolls, BJ; Krishen, A; Lopes, RD; Mahaffey, KW; Marquess, ML; McGuire, DK; Roe, MT; Russell, SD; Wilson, MD, 2017) |
| " The aim of this study was to compare the direct medical costs of smoking cessation therapies with varenicline, bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua over 5 time horizons: 2, 5, 10, and 20 years, and lifetime." | 3.78 | Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua. ( Cuesta, G; Lovato, P; Lutz, MA, 2012) |
| "To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion." | 3.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "To calculate incremental cost-utility ratios (cost per quality-adjusted life-year [QALY] gained) for bupropion (Zyban; GlaxoSmithKline; Gothenburg, Sweden), as compared to nicotine replacement therapy (NRT) in smoking cessation programs for a follow-up period of 20 years." | 3.73 | The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. ( Bolin, K; Lindgren, B; Willers, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Parikh, NS | 1 |
| Salehi Omran, S | 1 |
| Kamel, H | 1 |
| Elkind, MSV | 1 |
| Willey, JZ | 1 |
| Kittle, J | 1 |
| Lopes, RD | 1 |
| Huang, M | 1 |
| Marquess, ML | 1 |
| Wilson, MD | 1 |
| Ascher, J | 1 |
| Krishen, A | 1 |
| Hasselblad, V | 1 |
| Kolls, BJ | 1 |
| Roe, MT | 1 |
| McGuire, DK | 1 |
| Russell, SD | 1 |
| Mahaffey, KW | 1 |
| Langley, TE | 1 |
| Szatkowski, L | 1 |
| McNeill, A | 1 |
| Coleman, T | 1 |
| Lewis, S | 1 |
| Lutz, MA | 1 |
| Lovato, P | 1 |
| Cuesta, G | 1 |
| Svanström, H | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Bolin, K | 1 |
| Lindgren, B | 1 |
| Willers, S | 1 |
1 review available for bupropion and Stroke
| Article | Year |
|---|---|
Smoking-cessation pharmacotherapy for patients with stroke and TIA: Systematic review.
Topics: Bupropion; Female; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Randomized Co | 2020 |
5 other studies available for bupropion and Stroke
| Article | Year |
|---|---|
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.
Topics: Adult; Bupropion; Cardiotoxicity; Cardiovascular Diseases; Drug Discovery; Female; Humans; Male; Mid | 2017 |
Prescribing of nicotine replacement therapy to cardiovascular disease patients in England.
Topics: Adult; Benzazepines; Bupropion; Coronary Disease; Drug Prescriptions; England; General Practice; Hum | 2012 |
Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Coronary Disease; Costs and Cost Analysis; Dopamin | 2012 |
Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Benzazepines; Bupropion; Cardiovascular Dise | 2012 |
The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Topics: Adult; Aged; Bupropion; Chewing Gum; Cost-Benefit Analysis; Dopamine Uptake Inhibitors; Female; Hear | 2006 |